SeaStar Medical Holding Corporation (ICU)

US — Healthcare Sector
Peers: VIRI  ZVSA  SONN  REVB  QNRX  ALLR  KRBP  VRAX  BDRX  PALI  UNCY  APGN  IMMX  CNSP  EFTR  NAVB 

Automate Your Wheel Strategy on ICU

With Tiblio's Option Bot, you can configure your own wheel strategy including ICU - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ICU
  • Rev/Share 0.0497
  • Book/Share 0.0656
  • PB 5.485
  • Debt/Equity 0.6425
  • CurrentRatio 0.9647
  • ROIC -19.0956

 

  • MktCap 4028886.0
  • FreeCF/Share -1.7606
  • PFCF -0.2655
  • PE -0.1948
  • Debt/Assets 0.0478
  • DivYield 0
  • ROE 6.0184

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
ICU
Published: June 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

Cincinnati Children's Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their Real-Life Experience with the QUELIMMUNE Therapy DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that the QUELIMMUNE therapy will be featured in a two-part video series that will be available on the SeaStar Medical website. The videos describe the adoption and the use of the QUELIMMUNE therapy for pediatric patients at the nationally recognized Cincinnati Children's Hospital Medical …

Read More
image for news SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
ICU
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Read More
image for news SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
SeaStar Medical to Report First Quarter Financial Results on May 14, 2025
ICU
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress.

Read More
image for news SeaStar Medical to Report First Quarter Financial Results on May 14, 2025
SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time
ICU
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show.

Read More
image for news SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

About SeaStar Medical Holding Corporation (ICU)

  • IPO Date 2021-03-18
  • Website https://www.seastarmedical.com
  • Industry Biotechnology
  • CEO Mr. Eric Schlorff
  • Employees 19

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.